Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A third-generation lentivirus vector with a conditional packaging system

T Dull1, R Zufferey, M Kelly

  • 1Cell Genesys, Foster City, California 94404, USA.

Journal of Virology
|October 10, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ectopic FOXP3 Expression Preserves Primitive Features Of Human Hematopoietic Stem Cells While Impairing Functional T Cell Differentiation.

Scientific reports·2017
Same author

Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting.

Gene therapy·2015
Same author

Peripuberty stress leads to abnormal aggression, altered amygdala and orbitofrontal reactivity and increased prefrontal MAOA gene expression.

Translational psychiatry·2013
Same author

Exploiting microRNA regulation for genetic engineering.

Tissue antigens·2012
Same author

Post-natal cardiomyocytes can generate iPS cells with an enhanced capacity toward cardiomyogenic re-differentation.

Cell death and differentiation·2012
Same author

Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.

Gene therapy·2011
Same journal

Something old, something new? Herpesvirus genome packaging examined in light of lessons from the tailed bacteriophages.

Journal of virology·2026
Same journal

Receptor profiling and growth assessment of influenza A virus in porcine mammary and non-mammary tissues and derived cells.

Journal of virology·2026
Same journal

Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.

Journal of virology·2026
Same journal

Structure and functional analyses of vaccinia virus J5 protein reveal distinct determinants for entry-fusion complex assembly and activation.

Journal of virology·2026
Same journal

Coronavirus membrane protein with a fluorescent protein tag enables particle tracking for the study of virus assembly and egress in live cells.

Journal of virology·2026
Same journal

Disruption of the S1/S2 multibasic cleavage site attenuates infectious bronchitis virus, while S2' partially restores viral virulence and expands tissue tropism.

Journal of virology·2026
See all related articles

This study enhances lentivirus vector biosafety by modifying human immunodeficiency virus (HIV) gene usage. New vectors utilize fewer HIV genes, reducing replication risks for safer gene delivery.

Area of Science:

  • Molecular Biology
  • Virology
  • Gene Therapy

Background:

  • Lentivirus vectors derived from human immunodeficiency virus (HIV) offer efficient in vivo gene delivery but raise biosafety concerns.
  • HIV's complex genome includes essential regulatory genes (tat, rev) and accessory genes influencing virulence.

Purpose of the Study:

  • To develop novel biosafety features for lentivirus vectors by exploiting the HIV genome.
  • To create a safer lentivirus vector system with reduced reliance on essential HIV genes.

Main Methods:

  • Modified lentivirus vector constructs by deleting tat and rev genes.
  • Utilized chimeric long terminal repeat (LTR) promoters to offset tat gene requirement.
  • Employed a split-genome, conditional packaging system with trans-complementation for rev.

Related Experiment Videos

Main Results:

  • Chimeric LTR vectors demonstrated high transduction efficiency in neurons in vivo, independent of tat.
  • Deletion of rev gene made gag and pol expression dependent on trans-complementation.
  • Achieved high vector yields (up to 10(7) TU/ml) using a minimal set of HIV genes (gag, pol, rev).

Conclusions:

  • The developed third-generation lentivirus vector system uses a fractional set of HIV genes, enhancing biosafety.
  • The split-genome, conditional packaging design prevents the generation of replication-competent recombinants.
  • This improved lentivirus vector design facilitates further in vivo testing and application in gene therapy.